Marker Therapeutics (MRKR) Return on Capital Employed (2011 - 2026)
Marker Therapeutics (MRKR) reported Return on Capital Employed of 13.83% for Q1 2026, up 1352.0% year-over-year from 0.95% in Q1 2025, and up 13.73% quarter-over-quarter from 16.03% in Q4 2025.
Marker Therapeutics (MRKR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 15 years of Return on Capital Employed data on file, last reported at 13.83% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 13.83%, up 1352.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 13.83% (up 1352.0% YoY), and the FY2025 annual result was 14.0%, down 7.0% from the prior year.
- Return on Capital Employed improved to 13.83% in Q1 2026 per MRKR's latest filing, from 16.03% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 5.33% in Q3 2023 and troughed at 130.17% in Q3 2024.
- A 5-year average of 52.17% and a median of 42.55% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 9185 bps in 2023, then plunged 13550 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 27.65% in 2022, then sank by 246 bps to 95.73% in 2023, then surged by 82 bps to 17.25% in 2024, then climbed by 7 bps to 16.03% in 2025, then rose by 14 bps to 13.83% in 2026.
- Business Quant data shows MRKR's Return on Capital Employed at 13.83% in Q1 2026, 16.03% in Q4 2025, and 42.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -13.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.83% |
| Dec 31, 2025 | -16.03% |
| Sep 30, 2025 | -42.55% |
| Jun 30, 2025 | -56.92% |
| Mar 31, 2025 | -27.35% |
| Dec 31, 2024 | -17.25% |
| Sep 30, 2024 | -130.17% |
| Jun 30, 2024 | -100.77% |
| Mar 31, 2024 | -96.35% |
| Dec 31, 2023 | -95.73% |
| Sep 30, 2023 | 5.33% |
| Jun 30, 2023 | -7.58% |
| Mar 31, 2023 | -10.80% |
| Dec 31, 2022 | -27.65% |
| Sep 30, 2022 | -86.52% |
| Jun 30, 2022 | -86.77% |
| Mar 31, 2022 | -75.93% |
| Dec 31, 2021 | -69.09% |
| Sep 30, 2021 | -56.23% |
| Jun 30, 2021 | -45.17% |